Related Experiment Video
Updated: Aug 16, 2026

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks
Published on: November 10, 2016
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies
I B Bronstein1, S Vorobyev, A Timofeev
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Abstract:
DNA topoisomerase I (topo I) is the molecular target for the camptothecin group of anticancer drugs. These drugs are showing activity against a wide array of human tumors. Many data have indicated that the sensitivity of a tumor cell to the camptothecins is dependent on tumor topo I levels. Drug-sensitive cells have high levels of topo I. Unfortunately, there is still a relative lack of information on topo I levels in human malignancies. Because of this, we investigated topo I activity and immunoprotein levels in a variety of normal murine and human tissues, as well as tissues obtained from several carcinomas, lymphomas, and sarcomas. Flow cytometric analysis was also performed on the neoplastic specimens to determine the percentage of cycling cells. Topo I catalytic activity was detected in all normal tissues at a fairly constant level. The average topo I catalytic activity in normal mammalian tissues was 2.7 +/- 1.3 x 10(4) units/mg protein (range 1.1 to 5.0 x 10(4)). Topo I catalytic activity was much more variable in human malignancies and ranged from a low of 1.4 x 10(4) units/mg protein in a rhabdomyosarcoma to a high of 160 x 10(4) units/mg protein in a poorly differentiated ovarian carcinoma. Western blot analysis with either a mouse monoclonal antibody or scleroderma antibodies directed against topo I revealed that the elevated topo I catalytic activity levels in the malignant tissues are due to elevated amounts of topo I immunoprotein. It is possible that the high topo I levels that characterize several different types of human malignancies might indicate that these tumors would be sensitive to many of the new drugs that target topo I.
Insights
Cancer drug sensitivity hinges on DNA topoisomerase I (topo I) levels. This study found higher topo I in many human tumors, suggesting potential sensitivity to topo I-targeting anticancer drugs.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- DNA topoisomerase I (topo I) is the target for camptothecin anticancer drugs.
- Tumor cell sensitivity to these drugs correlates with topo I levels.
- Information on topo I levels in human malignancies is limited.
Purpose of the Study:
- To investigate topo I activity and protein levels in normal and cancerous human tissues.
- To assess the relationship between topo I levels and tumor type.
- To evaluate the potential of topo I levels as a predictor of drug sensitivity.
Main Methods:
- Enzyme activity assays to measure topo I catalytic activity.
- Western blot analysis to quantify topo I immunoprotein levels.
- Flow cytometry to determine the percentage of cycling cells in neoplastic specimens.
Main Results:
- Topo I activity was consistent in normal tissues (average 2.7 x 10^4 units/mg protein).
- Topo I activity varied significantly in human malignancies, with some showing much higher levels (up to 160 x 10^4 units/mg protein).
- Elevated topo I activity in tumors was attributed to increased topo I protein levels.
Conclusions:
- Human malignancies exhibit variable, often elevated, levels of DNA topoisomerase I.
- High topo I levels in tumors may indicate sensitivity to topo I-targeting anticancer therapies.
- Further research is warranted to explore the clinical implications of topo I levels in cancer treatment.
Related Concept Videos
DNA Helicases
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Abnormal Proliferation
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Intrinsic Apoptotic Pathway
Inhibitors of Bacterial DNA Synthesis

